AR123777A1 - Constructos de ácido nucleico para transcripción de arn va - Google Patents

Constructos de ácido nucleico para transcripción de arn va

Info

Publication number
AR123777A1
AR123777A1 ARP210102827A ARP210102827A AR123777A1 AR 123777 A1 AR123777 A1 AR 123777A1 AR P210102827 A ARP210102827 A AR P210102827A AR P210102827 A ARP210102827 A AR P210102827A AR 123777 A1 AR123777 A1 AR 123777A1
Authority
AR
Argentina
Prior art keywords
adenoviral
open reading
nucleic acid
reading frame
rna
Prior art date
Application number
ARP210102827A
Other languages
English (en)
Inventor
Ulrich Goepfert
Simon Auslaender
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR123777A1 publication Critical patent/AR123777A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Reivindicación 1: Un ácido nucleico de ARN VA adenoviral que comprende, en dirección 5’ a 3’ un promotor de ARN U6 humano y una secuencia codificante de ARN VA adenoviral de SEQ ID Nº 38. Reivindicación 2: Un ácido nucleico de ARN VA adenoviral que comprende, en dirección 5’ a 3’ un promotor inducible y una secuencia codificante de ARN VA adenoviral de SEQ ID Nº 38. Reivindicación 3: Un ADN que comprende un ácido nucleico de ARN VA adenoviral de acuerdo con una cualquiera de las reivindicaciones 1 ó 2, y un elemento de ADN que comprende un marco de lectura abierto E1A y un marco de lectura abierto E1B; o un marco de lectura abierto E2A y un marco de lectura abierto E4 o E4orf6; o un marco de lectura abierto rep y un marco de lectura abierto cap. Reivindicación 4: Una célula de mamífero o de insecto que comprende un ácido nucleico de ARN VA adenoviral de acuerdo con una cualquiera de las reivindicaciones 1 a 2 o un ADN de acuerdo con la reivindicación 3. Reivindicación 5: Un método para producir partículas de virus adenoasociado recombinante que comprende: proporcionar una célula de mamífero, cultivada en suspensión, que comprende un casete de expresión transgénica interespaciado entre dos ITR de AAV; marcos de lectura abiertos que codifican las proteínas E1A, E1B, E2A, E4 o E4orf6 adenovirales; un ácido nucleico de ARN VA adenoviral de acuerdo con una cualquiera de las reivindicaciones 1 a 2; marcos de lectura abiertos que codifican proteínas Rep / Cap adenoasociadas; cultivar la célula de mamífero; y aislar las partículas de rAAV de la célula o el medio de cultivo y, de esta manera, producir partículas de rAAV.
ARP210102827A 2020-10-15 2021-10-13 Constructos de ácido nucleico para transcripción de arn va AR123777A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20202010 2020-10-15

Publications (1)

Publication Number Publication Date
AR123777A1 true AR123777A1 (es) 2023-01-11

Family

ID=72964437

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102827A AR123777A1 (es) 2020-10-15 2021-10-13 Constructos de ácido nucleico para transcripción de arn va

Country Status (16)

Country Link
US (2) US12312606B2 (es)
EP (1) EP4229205B1 (es)
JP (1) JP2023546116A (es)
KR (1) KR20230085929A (es)
CN (1) CN116406425A (es)
AR (1) AR123777A1 (es)
AU (1) AU2021360197A1 (es)
CA (1) CA3197730A1 (es)
ES (1) ES3035361T3 (es)
HR (1) HRP20250766T1 (es)
HU (1) HUE071824T2 (es)
IL (1) IL302046A (es)
MX (1) MX2023004052A (es)
PL (1) PL4229205T3 (es)
TW (1) TW202223094A (es)
WO (1) WO2022079083A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4189077A1 (en) 2020-07-30 2023-06-07 Shape Therapeutics Inc. Stable cell lines for inducible production of raav virions
WO2025217034A1 (en) * 2024-04-07 2025-10-16 Spark Therapeutics, Inc. Compositions and methods for the regulation of recombinant adeno-associated virus production

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
CN1127527A (zh) 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
WO1996026742A1 (en) 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
EP1983057A3 (en) 1995-09-08 2009-01-07 Genzyme Corporation Improved AAV vectors for gene therapy
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
FR2743818B1 (fr) * 1996-01-23 1998-04-10 Agronomique Inst Nat Rech Constructions d'adn et vecteurs d'expression derives du gene de l'arn va i d'adenovirus
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
EP0912873B1 (de) 1996-07-16 2000-12-06 STEYR MANNLICHER Aktiengesellschaft & Co. KG Gewehr mit lösbarer laufbefestigung
JPH1033175A (ja) 1996-07-24 1998-02-10 Hisamitsu Pharmaceut Co Inc 組換えアデノ随伴ウイルスベクターの製造方法
IL128736A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania Methods using cre-lox for production of recombinant adeno-associated viruses
DE19650714A1 (de) 1996-12-06 1998-06-10 Melchner Harald Von Prof Dr Genfallen-Konstrukt zur Identifizierung und Isolierung von Genen
US6743620B1 (en) 1996-12-16 2004-06-01 Eisai Co., Ltd. Method for preparing retrovirus vector for gene therapy
CA2269661A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Recombinase-activatable aav packaging cassettes for use in the production of aav vectors
US6303302B1 (en) 1997-11-19 2001-10-16 The Whitehead Institute For Biomedical Research Regulation of fungal gene expression
AU3097399A (en) 1998-03-20 1999-10-11 Trustees Of The University Of Pennsylvania, The Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
KR20020057975A (ko) 1999-10-29 2002-07-12 오미야 히사시 유전자 도입 방법
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP1134287A1 (en) 2000-03-08 2001-09-19 Universite De Geneve A system to control the expression of a given gene using another gene that encodes a polypeptide with recombinant activity
AU2001257611A1 (en) 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
CA2416701A1 (en) 2000-07-21 2002-01-31 The United States Of America, As Represented By The Secretary Of Agricul Ture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
AU2002219841A1 (en) 2000-11-16 2002-05-27 Cornell Research Foundation Inc. Vectors for conditional gene inactivation
US7074611B2 (en) 2001-04-27 2006-07-11 Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof
DE10210139A1 (de) 2002-03-07 2003-10-23 Medigene Ag Helferkonstrukte für die Herstellung hybrider rAAV-Partikel unterschiedlicher AAV-Serotypen
WO2003084977A1 (en) 2002-04-04 2003-10-16 Xiao Xiao Gene expression control system and its use in recombinant virus packaging cell lines
US7267979B2 (en) 2002-07-01 2007-09-11 Pioneer Hi-Bred International, Inc. Method of controlling gene silencing using site specific recombination
EP1546397A4 (en) 2002-09-27 2007-10-31 Cold Spring Harbor Lab CELL BASED RNA INTERFERENCE AND ASSOCIATED METHODS AND COMPOSITIONS
FR2852021B1 (fr) * 2003-03-04 2007-12-07 Methodes et outils pour le criblage d'arn actifs in cellulo
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
EP1512742A1 (en) 2003-09-08 2005-03-09 Margarete Odenthal Conditional modification of sirnas expression
WO2005116225A1 (en) 2004-05-25 2005-12-08 Children's Hospital Medical Center Method for introducing and expressing rna in cells
DE602004002471T2 (de) 2004-06-22 2007-01-18 Alcatel Verfahren und System zur Beteitstellung einer Übertragungsverbindung für Datenstromverkehr
US20060110390A1 (en) 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
US7189561B2 (en) 2004-09-21 2007-03-13 Advec, Inc. Production of adenovirus vectors with reduced levels of replication competent adenovirus contamination
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
AU2006339519A1 (en) 2005-12-16 2007-09-13 The Uab Research Foundation Compositions and methods related to controlled gene expression using viral vectors
US20100173387A1 (en) 2006-04-28 2010-07-08 Universitat Autonoma De Barcelona Method for producing adenovirus vectors for gene therapy and dna sequences used therefor
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom
IL201999A (en) 2009-11-08 2017-10-31 Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity
DK2529020T3 (en) 2010-01-28 2018-08-06 Childrens Hospital Philadelphia SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
US20130058871A1 (en) 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
AU2013249202B2 (en) 2012-04-18 2018-08-09 The Children's Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using AAV capsid variants
CN104540382A (zh) 2012-06-12 2015-04-22 弗·哈夫曼-拉罗切有限公司 用于产生条件性敲除等位基因的方法和组合物
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
US10183978B2 (en) 2013-01-27 2019-01-22 Exemplar Genetics, Llc Animal models of duchenne muscular dystrophy
KR20240090694A (ko) 2013-07-22 2024-06-21 더 칠드런스 호스피탈 오브 필라델피아 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
EP3039129B1 (en) 2013-08-30 2018-06-27 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
WO2016057800A1 (en) 2014-10-09 2016-04-14 The Regents Of The University Of California Targeted disruption of a csf1-dap12 pathway member gene for the treatment of neuropathic pain
KR102243243B1 (ko) 2014-10-23 2021-04-22 리제너론 파마슈티칼스 인코포레이티드 신규한 cho 통합 부위 및 이의 용도
AU2016362317B2 (en) 2015-12-01 2023-03-16 Spark Therapeutics, Inc. Scalable methods for producing recombinant Adeno-Associated Viral (AAV) vector in serum-free suspension cell culture system suitable for clinical use
WO2017189683A1 (en) 2016-04-26 2017-11-02 Massachusetts Institute Of Technology Extensible recombinase cascades
WO2018096356A1 (en) 2016-11-28 2018-05-31 Horizon Discovery Limited Methods for conditional gene knock-out
WO2018150271A1 (en) * 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
AU2018281306B2 (en) 2017-06-07 2025-04-17 Spark Therapeutics, Inc. Enhancing agents for improved cell transfection and/or rAAV vector production
US20200332278A1 (en) 2017-06-16 2020-10-22 Universite De Strasbourg Methods to generate conditional knock-in models
MY207534A (en) 2017-06-30 2025-03-03 Spark Therapeutics Inc Aav vector column purification methods
EP3456822A1 (en) 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
WO2019217483A1 (en) * 2018-05-07 2019-11-14 Spark Therapeutics, Inc. Plasmid free aav vector producing cell lines
GB201816919D0 (en) 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
SG11202106217TA (en) * 2018-12-21 2021-07-29 Lonza Walkersville Inc Adeno-associated virus (aav) producer cell line and related methods

Also Published As

Publication number Publication date
KR20230085929A (ko) 2023-06-14
US12312606B2 (en) 2025-05-27
PL4229205T3 (pl) 2025-08-18
EP4229205C0 (en) 2025-05-14
IL302046A (en) 2023-06-01
TW202223094A (zh) 2022-06-16
WO2022079083A1 (en) 2022-04-21
JP2023546116A (ja) 2023-11-01
HUE071824T2 (hu) 2025-09-28
EP4229205A1 (en) 2023-08-23
CN116406425A (zh) 2023-07-07
US20220135954A1 (en) 2022-05-05
AU2021360197A9 (en) 2023-07-13
US20260103684A1 (en) 2026-04-16
ES3035361T3 (en) 2025-09-02
CA3197730A1 (en) 2022-04-21
EP4229205B1 (en) 2025-05-14
HRP20250766T1 (hr) 2025-08-15
MX2023004052A (es) 2023-05-03
AU2021360197A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
US20230116968A1 (en) Scalable production method for aav
Kotin Large-scale recombinant adeno-associated virus production
JP7562558B2 (ja) プラスミドシステム
US9249425B2 (en) Proviral plasmids and production of recombinant adeno-associated virus
AR123777A1 (es) Constructos de ácido nucleico para transcripción de arn va
Okada et al. Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes
PT1064393E (pt) Composicoes e metodos para a producao de virus adeno-associados recombinantes sem auxiliar
EP3722434B1 (en) Plasmid system
US20230323387A1 (en) Plasmid system
JPWO2020086881A5 (es)
US20230076955A1 (en) DNA Amplification Method
AR123948A1 (es) ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES
EP4317424A1 (en) Vector, method for preparing linear covalent bond closed dna using same, parvovirus vector preparation method, and parvovirus vector producing cell
US11427809B2 (en) Methods for isolating adeno-associated virus using a polydialkylammonium salt
AR129500A1 (es) Método para producir partículas de aav recombinante
US20260117255A1 (en) Plasmid system
Goldsmith et al. 520. The Effects of Transgene and Cassette Size on Recombinant AAV2 Production and Expression
JPWO2022079083A5 (es)
Leonard et al. 519. Selective Inactivation of Helper Adenovirus with High Hydrostatic Pressure for AAV-2 Vector Production
JPWO2022223954A5 (es)
AR132189A1 (es) Método para la producción de preparados de partículas de aav recombinantes
KR20260052122A (ko) 아데노-연관 바이러스(AAV) 기반 벡터의 생산을 위한 아데노바이러스 E2a 유전자의 변형된 서열 (변이체)
CN118460545A (zh) 一种诱导型表达Rep多肽的表达框
CN121816424A (zh) 用于生产基于腺相关病毒(AAV)的载体(变体)的腺病毒E2a基因的修饰的序列